(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to demonstrate that the performance of the modified Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved Plasmat® Secura H.E.L.P Apheresis System for use under the approved indication of the acute reduction of LDL-cholesterol from the plasma in populations for whom diet has been ineffective and maximum drug therapy has either been ineffective or not tolerated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers

NCT01138371

Familial Hypercholesterolemia

COMPLETED

Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy

NCT02326220

Heterozygous Familial Hypercholesterolemia

COMPLETED PHASE3

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

NCT02585895

Hypercholesterolemia

COMPLETED PHASE3

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

NCT07000136

Heterozygous Familial Hypercholesterolaemia

ACTIVE_NOT_RECRUITING PHASE3

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

NCT03135184

Homozygous Familial Hypercholesterolemia HoFH

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary study endpoint is the change in percent measurements of the pre-to-post apheresis LDL measurements between the approved H.E.L.P. system and the modified H.E.L.P. system. The secondary study endpoints are clinical lab profiles and device parameters analyzed at specific time points throughout the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A (Secura then Futura)

The Group Randomized first to the approved Plasmat® Secura apheresis system and then to the Plasmat® Futura apheresis system.

Group Type OTHER

Secura then Futura

Intervention Type DEVICE

Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.

B (Futura then Secura)

The Group Randomized first to the approved Plasmat® Futura apheresis system and then to the Plasmat® Secura apheresis system.

Group Type OTHER

Futura then Secura

Intervention Type DEVICE

Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Secura then Futura

Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.

Intervention Type DEVICE

Futura then Secura

Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is between 25 and 70 years of age (inclusive) at the time of randomization.
* Subject is an appropriate candidate for H.E.L.P. apheresis treatment for hypercholesterolemia according to current Plasmat® Secura approval criteria.
* Subject has received a minimum of two consecutive bi-monthly\* H.E.L.P. apheresis treatments using the Plasmat® Secura apheresis system \>30 days prior to the screening visit.
* Subject is willing to maintain cholesterol lowering dietary and drug therapies as prescribed through the course of the study.
* Subject is willing and able to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) Waiver.
* Sterile, post-menopausal, or using acceptable birth control for the duration of the study. Acceptable birth control is defined as having a vasectomized, postmenopausal, or sterile partner; the ongoing use of approved hormonal contraceptives, barrier method, or an intrauterine device; or abstinence.

* Every 14 days (±2 days)

Exclusion Criteria

* A History of a known sensitivity to heparin or ethylene oxide.
* A history of hemorrhagic diathesis, bleeding/clotting disorder, thrombocytopenia (defined as platelet count \< 150 x109/L), or for whom the use of heparin would cause excessive or uncontrolled anticoagulation or for whom adequate anticoagulation cannot be safely achieved (ie., hemophilia, recent surgery, acute internal bleeding, gastrointestinal ulcers).
* Females who are pregnant or lactating.
* Subjects\< 106 lbs. or \<48.2 kg in body weight; or whose weight is \>1.5 times their ideal weight.
* Certain cardiac impairments such as congestive heart failure, major arrhythmia, or diastolic blood pressure greater than 100 mm/Hg on two separate occasions at least 24 hours apart.
* Renal insufficiency defined as creatinine greater \>2.0 mg/dlL or is dependent upon renal dialysis.
* Untreated hypothyroidism; uncontrolled diabetes mellitus; or fasting triglycerides \>500 mg/dL.
* Serious systemic disease (e.g., advanced neoplasms, and acute hepatitis) including Immune system suppression or compromise, that could preclude survival to study completion.
* History of stroke within 6 months of the screening visit.
* Received thrombolytic treatment \< 7 days of screening.visit.
* Taken or requires a prohibited treatment \< 30 days prior to the Screening Visit, or requires a prohibited treatment at anytime during the course of the study.
* Neutropenia (neutrophil count \< 0.5 x109/L).
* History of liver disease or serum ALT and/or AST \> 2X upper limit of normal range.
* History of dementia.
* History of anemia (value outside the lower normal range).
* acetyl salicylic acid (ASA) \> 325 mg/day.
* Subject currently enrolled in another investigational study (does not apply to PMS for Secura device).
* Subject with any other medical condition that in the opinion of the investigator might put the subject at risk or interfere with his/her participation.
* Subject is unwilling or unable to comply with the protocol or to cooperate fully with the investigator or site personnel.

Minimum Eligible Age

25 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No